Related Experiment Videos
Carnitine palmitoyl transferase deficiency in malignant hyperthermia
G D Vladutiu1, K Hogan, I Saponara
1Department of Pediatrics, School of Medicine and Biomedical Sciences, State University of New York, Buffalo.
Muscle & Nerve
|May 1, 1993
Summary
Malignant hyperthermia susceptibility may be linked to carnitine palmitoyltransferase (CPT) deficiency. Some patients show reduced CPT enzyme activity and protein, suggesting a primary defect, while others exhibit milder deficiencies secondary to the condition.
Area of Science:
- Biochemistry
- Human Genetics
- Enzymology
Background:
- Malignant hyperthermia (MH) is a severe pharmacogenetic disorder of skeletal muscle.
- Carnitine palmitoyltransferase (CPT) is crucial for long-chain fatty acid transport into mitochondria.
- A potential link between CPT deficiency and MH susceptibility has been investigated.
Purpose of the Study:
- To investigate carnitine palmitoyltransferase (CPT) activity and protein levels in patients with susceptibility to malignant hyperthermia (MH).
- To determine if CPT deficiency is a primary or secondary defect in MH patients.
Main Methods:
- Quantification of CPT enzyme activity in EB-virus-transformed lymphoblasts from 7 MH-susceptible patients.
- Measurement of immunoreactive CPT enzyme protein using enzyme-linked immunosorbent assay (ELISA).
- Utilized lymphoblast cell lines from CPT-deficient muscle patients and normal individuals as controls.
Main Results:
- One MH patient exhibited significantly reduced CPT enzyme activity and immunoreactive protein, comparable to known CPT deficiency.
- The remaining MH patients showed CPT deficiency only when using the backward assay method.
- This suggests heterogeneity in CPT involvement in MH susceptibility.
Conclusions:
- A subset of individuals with malignant hyperthermia phenotype may have a primary carnitine palmitoyltransferase deficiency.
- Other MH patients might present with a milder, secondary enzyme deficiency.
- Further research is warranted to elucidate the precise role of CPT in MH pathophysiology.